Scandonest and associated names

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision

Table of contents

Current status
European Commission final decision

Overview

Use of Scandonest and associated names (mepivacaine) to be harmonised

Information for doctors and patients to be aligned across EU

On 31 May 2018, the European Medicines Agency (EMA) completed a review of Scandonest and associated names and recommended changes to the prescribing information in order to harmonise the way the medicine is used in the EU.

Key facts

About this medicine
Approved name
Scandonest and associated names
International non-proprietary name (INN) or common name
mepivacaine
Associated names
  • Biocaine
  • Scandicaine
Class
Anaesthetic
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-30/1455
Type
Article 30 referrals

This type of referral is triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to harmonise across the EU.
Key dates and outcomes
CHMP opinion date
31/05/2018
EC decision date
02/08/2018

All documents

Opinion provided by Committee for Medicinal Products for Human Use

European Commission final decision

  • List item

    Scandonest Article-30 referral - Use of Scandonest and associated names (mepivacaine) to be harmonised (PDF/78.31 KB)


    First published: 01/06/2018
    Last updated: 07/08/2018
    EMA/356909/2018 Rev. 1

  • List item

    Scandonest Article-30 referral - CHMP assessment report (PDF/209.67 KB)


    First published: 07/08/2018
    Last updated: 07/08/2018
    EMA/413109/2018

  • List item

    Scandonest Article-30 referral - Annex II (PDF/58.82 KB)


    First published: 07/08/2018
    Last updated: 07/08/2018

  • List item

    Scandonest Article-30 referral - Annex III (PDF/352.83 KB)


    First published: 01/06/2018
    Last updated: 07/08/2018

  • List item

    Scandonest Article-30 referral - Annex I (PDF/87.68 KB)


    First published: 15/09/2017
    Last updated: 07/08/2018
    EMA/594289/2017

    • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    News

    Related content

    How useful was this page?

    Add your rating